Search Results 831-840 of 17389 for alopecia

  1. A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM - Mayo Clinic

    current) related to prior anticancer therapy (excluding alopecia, lymphopenia, peripheral neuropathy, and ototoxicity, which are excluded only if ≥ Grade 3) ...

  2. A Study to Evaluate Tazemetostat and Pembrolizumab to Treat Advanced Urothelial Carcinoma - Mayo Clinic

    Note: patients with ≤ grade 2 neuropathy or ≤ grade 2 alopecia or ≤ grade 3 audiometric hearing loss are an exception to this criterion and may qualify for ...

  3. Mayo Clinic

    An experienced team of pediatric cancer experts diagnose and treat children who have brain tumors.

  4. Clinical trials - Physician Health Center

    Clinical trials are research studies that involve volunteer participants. These human studies help doctors better understand, diagnose, treat, and prevent ...

  5. Migraine Research Program - Videos

    View educational videos about migraine diagnosis, treatment and research from the Migraine Research Program at Mayo Clinic.

  6. Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors - Mayo Clinic

    Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration. Satisfactory laboratory ...

  7. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies - Mayo Clinic

    03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible toxicity that is not ...

  8. Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 - Mayo Clinic

    Significant autoimmune disease with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were ...

  9. MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer - Mayo Clinic

    Failure to recover to ≤Grade 1 from acute, reversible effects of prior chemotherapy, excluding alopecia regardless of interval since last treatment. NOTE ...

  10. A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib - Mayo Clinic

    Resolution of all toxicities from prior therapy to ≤ Grade 1 (or patient baseline) within 1 week prior to the first dose of study drug (excluding alopecia ...